TheStreet.com published article titled "IsoRay Takes Liberties With Lung Cancer Study Results to Prop Up Stock Price," which reported "To make up for the inability to deliver revenue growth — and prop up its stock price — IsoRay issues a lot of promotional press releases, some of which take liberties with clinical data using clever, selective editing." The article goes on to give the following example: IsoRay recently trumpeted a 100% survival at five years in high risk patients being treated with Cesium-131 without mentioning that the comparable five year survival rate for patients undergoing surgery alone is 98%.
Our investigation concerns whether the Company board of directors has breached its fiduciary duties to shareholders, grossly mismanaged the Company, and/or committed abuses of control in connection with the foregoing.
If you own IsoRay shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:
Robert I. Harwood, Esq.
Benjamin I. Sachs-Michaels, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400, (212)935-7400
Follow us on Twitter: @HarwoodFeffer
Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.
The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/harwood-feffer-llp-announces-investigation-of-isoray-inc-300087962.html
SOURCE Harwood Feffer LLP